{"entity":{"id":"nct06531291","kind":"trial","name":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","aka":[],"tldr":"A phase 2 trial of serplulimab and surufatinib in gallbladder cancer and other biliary tract cancers, run by RenJi Hospital, not yet recruiting.","summary":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation is a phase 2 interventional study registered as NCT06531291 by RenJi Hospital, with a registry enrolment figure of 80 participants, started 2024-08-10 and due to reach its primary completion in 2027-08-09. Interventions recorded: Surufatinib, Serplulimab, standard chemotherapy. Conditions listed: ESCC, Biliary Tract Cancer, Gastric Cancer, Pancreas Cancer. Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06531291","url":"https://clinicaltrials.gov/study/NCT06531291"}],"tags":["ctgov-ingest","gallbladder-deep-dive"],"related":[],"cancers":["gallbladder","cholangiocarcinoma","biliary-tract-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["serplulimab","surufatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06531291","phase":"2","setting":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation: A Single-arm, Multi-cohort, Open-label, Single-center, Prospective, Exploratory Clinical Study","sponsor":"RenJi Hospital","participation":[{"nct":"NCT06531291","source":"https://clinicaltrials.gov/study/NCT06531291","fetchedAt":"2026-10-07T16:54:46.480Z","studySha256":"9dae57c54fb346239c7338b9000e2c60022ec9f4e3afdce3b76bf74652150c02","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2024-07-31","leadSponsor":"RenJi Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":80,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2024-08-10","startedType":"estimated","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06531291/","neighbours":{"cancer":[{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/"},{"id":"surufatinib","kind":"drug","name":"Surufatinib","route":"/drugs/surufatinib/"}],"term":[{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/"}]}}